CDEK by Data4ThePeople
Sign in Sign up
← All organizations

X4 Pharmaceuticals

For profitContributed to NME

Also known as: X4 Pharmaceuticals | X4 Pharmaceuticals, Inc. | X4 PHARMS

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 3

First clinical trial

Jan 1, 2016

First marketed drug

Apr 26, 2024

First NDA

Apr 26, 2024

Last known activity

Feb 24, 2025

Timeline

2010s

  1. Jun 1, 2012

    X4 Pharmaceuticals— Founded

  2. Mar 14, 2019

    Arsanis, Inc.— Acquired

2020s

  1. Apr 26, 2024

    Mavorixafor— NDA Organization

Drugs by trial phase (8 distinct, 12 trials)

Phase 3 (1 own, 0 via acquisition)

Phase 2 (2 own, 1 via acquisition)

Phase 1 (4 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (1)

Subsidiaries (1 direct, 2 total across the full acquisition tree)

Recent trials (22)

Details

Founded
Cambridge, MA, US Jun 1, 2012
First NDA
Apr 26, 2024
Last known activity
Feb 24, 2025

Designations held

  • Orphan drug
  • Fast track
  • Priority review